Q-omics provides the consensus-scored MTURN profile across patient tissues and cancer cell-line models. MTURN expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTURN is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MTURN protein abundance shows 28,949 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where MTURN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTURN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTURN survival associations across molecular data types. MTURN RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTURN RNA expression–survival associations across cancer types. High MTURN expression shows unfavorable associations in SKCM, but favorable associations in KIRC, LUAD, UCS, MESO and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTURN RNA expression.
This table summarizes MTURN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MTURN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTURN shows lower tumor expression in KIRC, KIRP, BLCA, THCA, KICH and LUAD. The KIRC box plot shows higher MTURN RNA expression in normal versus tumor tissue (log2 FC = −3.183, t-test p < 0.001).
This table shows molecular features associated with MTURN in patient tissues and cancer cell lines. In patient samples, MTURN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTURN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_SCLC.
